Leo Kager

List of Publications by Year
in descending order

70 papers	4,037 citations	201674 27 h-index	118850 62 g-index
85 all docs	85 docs citations	85 times ranked	4897 citing authors

#	Article	IF	Citations
1	Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. Cancer, 2022, 128, 1787-1800.	4.1	8
2	Clear cell sarcoma of the kidney in Austrian children: Longâ€term survival after relapse. Pediatric Blood and Cancer, 2021, 68, e28860.	1.5	7
3	Occurrence of autoimmune pancreatitis after chronic immune thrombocytopenia in a Caucasian adolescent. Clinical Journal of Gastroenterology, 2021, 14, 918-922.	0.8	1
4	Extraosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl. Clinical Case Reports (discontinued), 2021, 9, e04094.	0.5	0
5	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. European Journal of Cancer, 2021, 151, 150-158.	2.8	19
6	Systematic review of the immunological landscape of Wilms tumors. Molecular Therapy - Oncolytics, 2021, 22, 454-467.	4.4	25
7	Osteosarcoma-Approach to Therapy. Pediatric Oncology, 2021, , 91-109.	0.5	10
8	Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. Cancers, 2021, 13, 5016.	3.7	6
9	Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients. Cancer Management and Research, 2021, Volume 13, 8989-8998.	1.9	7
10	Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093789.	3.2	8
11	Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood, 2020, 136, 2638-2655.	1.4	64
12	Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. Journal of Clinical Oncology, 2020, 38, 823-833.	1.6	45
13	Novel Compound Heterozygous Mutations in Two Families With Bernardâ€"Soulier Syndrome. Frontiers in Pediatrics, 2020, 8, 589812.	1.9	4
14	Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 667-675.	0.8	6
15	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
16	Polymerase Î´ deficiency causes syndromic immunodeficiency with replicative stress. Journal of Clinical Investigation, 2019, 129, 4194-4206.	8.2	41
17	Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood. Memo - Magazine of European Medical Oncology, 2018, 11, 54-58.	0.5	1
18	Highâ€dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survivalâ€"The Gesellschaft fÃ¼r PÃdiatrische Onkologie und HÃmatologie (GPOH) experience. Pediatric Blood and Cancer, 2018, 65, e26746.	1.5	35

#	Article	IF	Citations
19	Thoracic Actinomycosis With Infiltration of the Spine: An Oncological Pitfall. Journal of Pediatric Hematology/Oncology, 2018, 40, 468-471.	0.6	5
20	Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literatureâ€"A report from the SIOP Renal Tumor Study Group. Pediatric Blood and Cancer, 2018, 65, e26849.	1.5	11
21	Pharmacogenomics and Hematologic Diseases. , 2018, , 79-91.		0
22	Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy â€" Case report. Pediatric Hematology and Oncology, 2018, 35, 218-224.	0.8	11
23	Targeted mutation screening of 292 candidate genes in 38 children with inborn haematological cytopenias efficiently identifies novel diseaseâ€causing mutations. British Journal of Haematology, 2018, 182, 251-258.	2.5	12
24	High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients. Sarcoma, 2018, 2018, 1-11.	1.3	9
25	Osteosarkome. , 2018, , 509-525.		0
26	Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia. Haematologica, 2017, 102, e73-e75.	3.5	12
27	Denosumab treatment for progressive skull base giant cell tumor of bone in a 14Âyear old female â€" a case report and literature review. Italian Journal of Pediatrics, 2017, 43, 32.	2.6	16
28	Band 3 null^{VIENNA}, a novel homozygous SLC4A1 p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal renal tubular acidosis. Pediatric Blood and Cancer, 2017, 64, e26227.	1.5	19
29	Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncology, 2017, 13, 357-368.	2.4	178
30	Advances in the management of osteosarcoma. F1000Research, 2016, 5, 2767.	1.6	105
31	Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of thePKLRGene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia. Pediatric Blood and Cancer, 2016, 63, 914-916.	1.5	6
32	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1396-1408.	10.7	356
33	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology, 2016, 34, 3195-3203.	1.6	105
34	NF-ÎºB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation. Journal of Clinical Immunology, 2016, 36, 533-540.	3.8	113
35	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24â€"25, 2015. Workshop Report. Clinical Sarcoma Research, 2016, 6, 3.	2.3	14
36	Multiple relapses in highâ€grade osteosarcoma: When to stop aggressive therapy?. Pediatric Blood and Cancer, 2015, 62, 529-530.	1.5	6

#	Article	IF	Citations
37	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2279-2287.	1.6	329
38	Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1025-1028.	3.3	9
39	Absence of Band 3 in Severe Dyserythropoietic/Hemolytic Anemia with Complete Distal Renal Acidosis and a Novel Homozygous Exon 12 C.1430C>a (p.Ser477X) SLC4A1 Gene Mutation. Blood, 2015, 126, 945-945.	1.4	1
40	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1.. Journal of Clinical Oncology, 2015, 33, 10512-10512.	1.6	4
41	Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein. PLoS ONE, 2014, 9, e87602.	2.5	34
42	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. Cancer Genetics, 2014, 207, 434-436.	0.4	14
43	Long-term survival of patients suffering from solid extra-cranial neoplasias after dendritic cell-based cancer immune therapy.. Journal of Clinical Oncology, 2014, 32, 3096-3096.	1.6	5
44	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 2303-2312.	1.6	161
45	MAP plus maintenance pegylated interferon Î±-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 â€œgood responseâ€•randomization.. Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	14
46	MAP plus maintenance pegylated interferon Î±-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	4
47	Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. European Journal of Pediatrics, 2012, 171, 1711-1715.	2.7	24
48	Results of children with renal tumors treated in the Austrianâ€"Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria. Memo - Magazine of European Medical Oncology, 2012, 5, 289-295.	0.5	2
49	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. Journal of Clinical Oncology, 2012, 30, 10081-10081.	1.6	3
50	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	1.5	120
51	Osteosarcoma in very young children. Cancer, 2010, 116, 5316-5324.	4.1	54
52	Old drugâ€"New insightsâ€"Better treatment?. Leukemia Research, 2010, 34, 1558-1559.	0.8	0
53	Review of mifamurtide in the treatment of patients with osteosarcoma. Therapeutics and Clinical Risk Management, 2010, 6, 279.	2.0	86
54	Synchronous and Metachronous Lung Metastases in High-grade Osteosarcoma. Japanese Journal of Clinical Oncology, 2010, 40, 94-95.	1.3	4

#	Article	IF	Citations
55	Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy. Memo - Magazine of European Medical Oncology, 2009, 2, 65-70.	0.5	2
56	Pharmacogenetics in Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 39-51.	3.4	55
57	High-dose Methotrexate: The Rationaleâ€¦. Journal of Pediatric Hematology/Oncology, 2009, 31, 224-225.	0.6	3
58	Antileukemic drug effects in childhood acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology, 2008, 1, 401-413.	3.1	1
59	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	8.4	75
60	Cutting Edge: A Hypomorphic Mutation in Igî² (CD79b) in a Patient with Immunodeficiency and a Leaky Defect in B Cell Development. Journal of Immunology, 2007, 179, 2055-2059.	0.8	74
61	Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica, 2007, 92, 1561-1564.	3.5	55
62	Pharmacogenomics of acute lymphoblastic leukemia. Current Opinion in Hematology, 2006, 13, 260-265.	2.5	38
63	Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 2006, 24, 1535-1541.	1.6	122
64	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	8.2	129
65	Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.. Blood, 2005, 106, 1458-1458.	1.4	1
66	A substrate specific functional polymorphism of human Î³-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics and Genomics, 2004, 14, 557-567.	5.7	83
67	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441.	1.4	38
68	Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology, 2003, 21, 2011-2018.	1.6	765
69	Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes and Cancer, 2000, 28, 329-336.	2.8	101
70	Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor. Frontiers in Immunology, 0, 13, .	4.8	1